Concomitant Medications for Progressive Supranuclear Palsy

Author:

Iyer Jay M.1,Gunzler Douglas2,Lang Anthony E.3,Golbe Lawrence I.4,Pantelyat Alexander5,Boxer Adam L.6,Wills Anne-Marie7,

Affiliation:

1. Departments of Molecular and Cellular Biology and Statistics, Harvard University, Cambridge, Massachusetts

2. Population Health Research Institute, Center for Health Care Research and Policy, MetroHealth Medical Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio

3. Edmond J. Safra Program in Parkinson’s Disease, Rossy Progressive Supranuclear Palsy Centre, Movement Disorders Clinic, Krembil Brain Institute, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, Toronto, Ontario, Canada

4. Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey

5. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland

6. Memory and Aging Center, Department of Neurology, University of California, San Francisco

7. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Abstract

This secondary analysis of a randomized clinical trial examines changes in the progression of progressive supranuclear palsy (PSP) associated with 31 concomitant medication classes used by study participants over 1 year.

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3